{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:59:17Z","timestamp":1790438357549,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008052","name":"Foundation Alfonso Martin Escudero","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jconrel.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T05:01:46Z","timestamp":1389416506000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon"],"prefix":"10.1016","volume":"178","author":[{"given":"Huiyuan","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.01.003_bb0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1167\/iovs.09-3672","article-title":"Intravitreal crystalline drug delivery for intraocular proliferation diseases","volume":"51","author":"Cheng","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0039-6257(85)90208-5","article-title":"Proliferative vitreoretinopathy and chemotherapeutic agents","volume":"29","author":"Peyman","year":"1985","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3928\/1542-8877-20030701-05","article-title":"Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy","volume":"34","author":"Shinohara","year":"2003","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/BF00166311","article-title":"Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy","volume":"229","author":"Khawly","year":"1991","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","article-title":"Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery","volume":"30","author":"Kumar","year":"2002","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0040","first-page":"719","article-title":"Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo","volume":"26","author":"Wiedemann","year":"1985","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bjo.2007.133587","article-title":"Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle","volume":"92","author":"Cheng","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1167\/iovs.12-11172","article-title":"Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system","volume":"54","author":"Chhablani","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/jop.2012.0205","article-title":"Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin","volume":"29","author":"Hartmann","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.exer.2013.09.001","article-title":"Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles","volume":"116","author":"Nieto","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/pssa.200306519","article-title":"Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions","volume":"197","author":"Anderson","year":"2003","journal-title":"Phys. Status Solidi A"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0070","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1016\/j.biomaterials.2013.07.049","article-title":"Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics","volume":"34","author":"Martinez","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0075","series-title":"Porous Silicon in Practice: Preparation, Characterization, and Applications","author":"Sailor","year":"2012"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0080","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1039\/c1cc10993f","article-title":"Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics","volume":"47","author":"Wu","year":"2011","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0085","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1021\/nn800592q","article-title":"Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles","volume":"2","author":"Wu","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0090","doi-asserted-by":"crossref","first-page":"11636","DOI":"10.1021\/ja0511671","article-title":"Biosensing using porous silicon double-layer interferometers: reflective interferometric Fourier transform spectroscopy","volume":"127","author":"Pacholski","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0095","series-title":"Adsorption, Surface Area and Porosity","author":"K.S.W.","year":"1982"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/ja01269a023","article-title":"Adsorption of gases in multimolecular layers","volume":"60","author":"Brunauer S.","year":"1938","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/cm981006e","article-title":"Relations between pore structure parameters and their implications for characterization of MCM-41 using gas adsorption and X-ray diffraction","volume":"11","author":"Kruk","year":"1999","journal-title":"Chem. Mater."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0110","first-page":"1907","article-title":"A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3\u2032,5\u2032-cyclic monophosphate for proliferative vitreoretinopathy","volume":"18","author":"Kim","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1076\/ceyr.18.3.161.5366","article-title":"Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA)","volume":"18","author":"Cheng","year":"1999","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00347-007-1662-2","article-title":"New developments in retinal detachment surgery","volume":"105","author":"Bartz-Schmidt","year":"2008","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.jconrel.2014.01.003_bb0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0181-5512(04)96264-X","article-title":"Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy","volume":"27","author":"Scheer","year":"2004","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02308080","article-title":"Control of experimental massive periretinal proliferation by daunomycin: dose\u2013response relation","volume":"220","author":"Wiedemann","year":"1983","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF02134142","article-title":"Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit","volume":"221","author":"Santana","year":"1984","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0140","first-page":"627","article-title":"Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation","volume":"17","author":"Hou","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0145","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/jop.1994.10.561","article-title":"Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations","volume":"10","author":"Rahimy","year":"1994","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2008.03.017","article-title":"Porous silicon in drug delivery devices and materials","volume":"60","author":"Anglin","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1113\/jphysiol.1959.sp006151","article-title":"Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago crassicaudatus Agisymbanus)","volume":"145","author":"Davson","year":"1959","journal-title":"J. Physiol."},{"key":"10.1016\/j.jconrel.2014.01.003_bb0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-0-387-31701-4_2","article-title":"Porous silicon: morphology and formation mechanisms","volume":"39","author":"Zhang","year":"2006","journal-title":"Mod. Asp. Electrochem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T23:23:02Z","timestamp":1647991382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":33,"alternative-id":["S0168365914000200"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.01.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}